查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球重组蛋白市场评估：按产品、宿主细胞、应用、最终用户、地区、机会、预测（2017-2031）
市场调查报告书
商品编码
1408047

全球重组蛋白市场评估：按产品、宿主细胞、应用、最终用户、地区、机会、预测（2017-2031）

Recombinant Proteins Market Assessment, By Product, By Host Cell, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 204 Pages | 商品交期: 3-5个工作天内

价格

全球重组蛋白市场规模预计到2023年将达到25.1亿美元，到2031年将达到64.7亿美元，在2024-2031年预测期内复合年增长率为12.57%。 诊断和探索性研究领域的市场取得了显着成长。 近年来到期的生物製品专利数量不断增加，推动了市场需求。 预计 2022 年至 2027 年间，约 31 种生物製剂将失去独占权，创造庞大的市场需求。

生物技术领域不断增加的研发支出正在推动全球重组蛋白市场的显着成长。 由于重组蛋白在医疗、研究和生技领域的应用不断扩大，预计在预测期内对重组蛋白产品的需求将会增加。 此外，癌症、自体免疫疾病和糖尿病等慢性病的盛行率不断上升，需要生物製剂治疗，约占生物製剂市场的60%，重组蛋白市场的需求不断增加，预计将吸引100%的公司。 然而，重组蛋白生产的特殊要求和产品的高成本是市场的限制因素。

生物製品专利到期数量增加

越来越多的生物製品专利到期正在推动重组蛋白市场的成长。 生物製剂是由活细胞製成的复杂分子，用于治疗多种疾病，包括癌症、自体免疫疾病和慢性肾臟病。 多个重磅生物製剂的专利已经到期或计划到期，推动了生物相似药和生物相似药的发展。 这些专利的到期为生物相似药和生物后续产品的开发创造了机会，推动了市场成长。

增加研发投入

研发支出的增加对重组蛋白市场产生了重大影响。 增加的投资正在促进创新蛋白质体学和基因组学技术的发展，并促进重组蛋白的生产。 预计亚太地区研发活动的增加尤其明显，为市场进入者提供潜在的成长机会。 研发支出的快速成长是市场扩张的关键驱动力。

预计细胞激素和生长因子在预测期内将占主导地位

由于细胞激素和生长因子在癌症、COVID-19、细胞培养、传染病和伤口癒合研究中发挥重要作用，因此预计将占据主导地位。 慢性病盛行率的增加和治疗需求的增加增加了对重组蛋白产品的需求。 对这些因子的研究和开发正在推动细胞因子和生长因子领域的主导地位。

北美可望引领重组蛋白市场

北美主导全球重组蛋白市场。 2022 年，北美将占据大部分收入份额，并预计未来将保持这一地位。 该地区的优势在于政府为製药业的研发提供资助策略、增加研发项目以及有利的政府资助。 美国占北美市场最大份额。 公司之间日益激烈的竞争和最终用户的多样化使用正在促进产品管道的扩展、新技术的开发和生物加工工具的进步。

未来市场情境

全球重组蛋白市场前景广阔，预计未来几年将显着成长。 市场驱动因素包括慢性病盛行率上升、研究和学术领域越来越多地采用生命科学和技术，以及领先的製药和生物技术公司的大量存在。 由于研究活动、新产品开发和最终用户采用率的增加，亚太地区预计将显着成长。 预计该市场将由细胞激素、生长因子、抗体和免疫检查点蛋白等产品主导。 该市场的主要参与者包括 Thermo Fisher Scientific, Inc.（美国）、R&D Systems（美国）、Abcam plc（英国）和 Merck KGaA（德国）。 除了医学之外，重组蛋白还用于农业、食品生产和生物工程，预计在不久的将来需求将进一步增加。

本报告研究和分析了全球重组蛋白市场，提供市场规模和预测、市场动态、主要参与者现状和前景等。

目录

第一章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第四章全球重组蛋白市场展望（2017-2031）

  • 市场规模与预测
    • 金额
    • 数量
  • 按产品
    • 细胞激素/生长因子
    • 抗体
    • 免疫检查点蛋白
    • 病毒抗原
    • □
    • 重组调节蛋白
    • 荷尔蒙
    • 其他
  • 依宿主细胞分类
    • 哺乳动物系统
    • 昆虫细胞
    • 酵母/真菌
    • 细菌细胞
    • 其他
  • 依用途
    • 药物发现/开发
    • 学术研究
    • 生物製药生产
    • 生技研究
    • 诊断
    • 其他用途
  • 按最终用户
    • 製药公司、生技公司
    • 学术/研究机构
    • 临床研究组织
    • 诊断实验室
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 市占率：依公司划分（2023 年）

第 5 章全球重组蛋白市场展望：按地区划分（2017-2031 年）

  • 北美
    • 市场规模与预测
    • 按产品
    • 依宿主细胞分类
    • 依用途
    • 按最终用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 南美洲
    • 巴西
    • 阿根廷
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印尼
    • 菲律宾
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 南非

第 6 章市场地图（2023 年）

  • 按产品
  • 依宿主细胞分类
  • 依用途
  • 按最终用户
  • 按地区

第七章宏观环境与产业结构

  • 需求与供给分析
  • 进出口分析 - 数量与价值
  • 供应/价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 抑製成长的因素（问题、限制因素）

第 9 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/新技术

第十章公司主要情况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析（2023 年）
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家公司进入市场）
  • 专利分析（如果适用）

第11章价格分析

第 12 章案例研究

第十三章主要公司展望

  • Abbvie Inc.
  • Amgen Inc.
  • Bio-Rad Laboratories Inc.
  • Eli Lilly and Company
  • Merck KGaA
  • Novo Nordisk AS
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Novartis AG
  • GlaxoSmithKline PLC
  • Novavax Inc.
  • Pfizer Inc.

第 14 章策略建议

第十五章关于我们公司，免责声明

Product Code: MX10843

Global Recombinant Proteins market size was valued at USD 2.51 billion in 2023, and is expected to reach USD 6.47 billion in 2031, with a CAGR of 12.57% for the forecast period between 2024 and 2031F. The recombinant protein market has registered significant growth in the field of diagnostic and exploratory research. The increase in the number of biologics patents expiring recently is driving demand for the recombinant protein market. About 31 biologics will lose exclusivity between 2022 and 2027 which is expected to create huge demand in the market.

Increasing expenditure on research and development in the field of biotechnology is promoting significant growth in the global recombinant proteins market. Due to the expansion of applications of recombinant proteins in the domain of medicine, research, and biotechnology, the demand for recombinant protein products is expected to increase during the forecast period. Additionally, the growing prevalence of chronic diseases like cancer, auto-immune diseases, and diabetes require biologics for treatment and contribute to about 60% of the biologics market, which is expected to draw more business in the recombinant proteins market. However, specific requirements of recombinant protein production and high cost of products are some of the factors restraining recombinant proteins market.

For instance, in June 2022, Navigo Proteins GmbH, a leading provider of affinity ligands for customized chromatography solutions and protein engineering, developed an affinity resin to capture the glycoprotein gp64, an unwanted contaminant from the baculovirus insect cell production system. By effectively utilizing precision capturing technology, Navigo was able to create a Precision X ligand that binds to the gp64 contaminant.

Increase in Number of Biologics Patent Expiration

The increasing number of biologics patent expiry is driving the growth of the recombinant proteins market. Biologics are complex molecules produced from living cells and are used to treat various diseases such as cancer, autoimmune diseases, and chronic kidney disease. Patents for several blockbuster biologics have expired or are set to expire, leading to the development of biosimilars and follow-on biologics. The expiration of these patents has created opportunities for the development of biosimilars and follow-on biologics, which are driving the growth of the recombinant proteins market.

According to The Center for Biosimilar, by 2023, patents on nearly 20 oncology biologics will expire. The highest-earning drug, Humira is losing exclusivity in the year 2023, opening a huge opportunity for the biosimilar market. Johnson & Johnson's Stelara is going off-patent in the second half of 2023 which is a promising candidate for the biosimilar market.

Increasing Investment in Research and Development

The increasing expenditure on research and development is significantly impacting the recombinant proteins market. The heightened investment is driving the development of innovative proteomic and genomic techniques, thereby fostering the production of recombinant proteins. The growing R&D initiatives are particularly notable in Asia-Pacific, which is expected to offer potential growth opportunities for market players. The surge in research and development spending is a key driver propelling the expansion of the recombinant proteins market. In February 2023, in a seed extension round, Canadian startup Future Fields secured USD 11.2 million to expand the use of fruit flies as high-value recombinant protein production machines. The firm aims to produce recombinant proteins at a large scale in 10,000 square feet of manufacturing space.

Cytokines and Growth Factors are Expected to Dominate During Forecast Period

The cytokines and growth factors segment is expected to dominate due to its vast role in research in cancer, COVID-19, cell culture, infectious diseases, and wound healing. The increasing prevalence of chronic diseases and their growing treatment requirements has led to an increase in demand for recombinant protein products. Research and development around these factors are propelling the dominance of cytokines and growth factors segment. In September 2023, Sino Biological, Inc. launched several products for biological research including four high-quality recombinant cytokines and GMP grade cytokines.

North America is Expected to be Lead the Recombinant Proteins Market

North America dominates the global recombinant proteins market. In 2022, North America accounted for a significant portion of the revenue share, and it is expected to maintain its position in the coming years. The region's dominance can be attributed to the availability of funding government initiatives for R&D in the pharmaceutical industry, more R&D programs, and a favorable funding from the government. The United States accounted for the largest share in the North America recombinant proteins market. The growth in competition among players and diverse applications by end-users has contributed to the expansion of product pipelines, the development of new technologies, and the advancement of bioprocessing tools.

Future Market Scenario

The outlook for the global recombinant proteins market appears to be promising, with significant growth expected in the coming years. The market is driven by factors such as the rising prevalence of chronic diseases, the growing adoption of life science techniques in research and academia, and the huge presence of major pharmaceutical and biotechnology companies. Asia-Pacific is projected to witness significant growth due to increasing research activities, new product development, and expanding applications by end-users. The market for recombinant proteins is expected to be dominated by products such as cytokines, growth factors, antibodies, and immune checkpoint proteins. Key players in the recombinant proteins market include Thermo Fisher Scientific, Inc. (US), R&D Systems (US), Abcam plc (UK), Merck KGaA (Germany), and others. Apart from healthcare, recombinant proteins are used in agriculture, food production, and bioengineering, which is further expected to increase demand in the near future.

Key Players Landscape and Outlook

Market players are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products using a variety of strategies. To gain market share, companies are expanding the range of products they offer. Industry participants use a variety of growth methods, including collaborations, mergers and acquisitions, product launches, and the development of new goods, to bolster their position in the market.

In January 2022, Thermo Fisher Scientific Inc. completed the acquisition of PeproTech, Inc. for a total cash purchase price of approximately USD 1.85 billion. PeproTech was a leading manufacturer of recombinant proteins in the United States. The acquisition strengthened the recombinant portfolio of Thermo Fisher Scientific.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Recombinant Proteins Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Product
    • 4.2.1. Cytokines and Growth Factors
      • 4.2.1.1. Interferons (IFNs)
      • 4.2.1.2. Interleukins (ILs)
      • 4.2.1.3. Others
    • 4.2.2. Antibodies
    • 4.2.3. Immune Checkpoint Proteins
    • 4.2.4. Virus Antigens
    • 4.2.5. Enzymes
      • 4.2.5.1. Kinases
      • 4.2.5.2. Metabolic enzymes
      • 4.2.5.3. Others
    • 4.2.6. Recombinant Regulatory Protein
    • 4.2.7. Hormones
    • 4.2.8. Others
  • 4.3. By Host Cell
    • 4.3.1. Mammalian Systems
    • 4.3.2. Insect Cells
    • 4.3.3. Yeast and Fungi
    • 4.3.4. Bacterial Cells
    • 4.3.5. Others
  • 4.4. By Application
    • 4.4.1. Drug Discovery and Development
      • 4.4.1.1. Biologics
      • 4.4.1.2. Vaccines
      • 4.4.1.3. Cell and Gene Therapy
    • 4.4.2. Academic Research Studies
    • 4.4.3. Biopharmaceutical Production
    • 4.4.4. Biotechnology Research
    • 4.4.5. Diagnostics
    • 4.4.6. Other Applications
  • 4.5. By End-user
    • 4.5.1. Pharmaceutical and Biotechnology Companies
    • 4.5.2. Academics and Research Institutions
    • 4.5.3. Clinical Research Organization
    • 4.5.4. Diagnostic Laboratories
    • 4.5.5. Others
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. South America
    • 4.6.5. Middle East & Africa
  • 4.7. By Company Market Share (%), 2023

5. Global Recombinant Proteins Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Product
      • 5.1.2.1. Cytokines and Growth Factors
      • 5.1.2.1.1. Interferons (IFNs)
      • 5.1.2.1.2. Interleukins (ILs)
      • 5.1.2.1.3. Others
      • 5.1.2.2. Antibodies
      • 5.1.2.3. Immune Checkpoint Proteins
      • 5.1.2.4. Virus Antigens
      • 5.1.2.5. Enzymes
      • 5.1.2.5.1. Kinases
      • 5.1.2.5.2. Metabolic enzymes
      • 5.1.2.5.3. Others
      • 5.1.2.6. Recombinant Regulatory Protein
      • 5.1.2.7. Hormones
      • 5.1.2.8. Others
    • 5.1.3. By Host Cell
      • 5.1.3.1. Mammalian Systems
      • 5.1.3.2. Insect Cells
      • 5.1.3.3. Yeast and Fungi
      • 5.1.3.4. Bacterial Cells
      • 5.1.3.5. Others
    • 5.1.4. By Application
      • 5.1.4.1. Drug Discovery and Development
      • 5.1.4.1.1. Biologics
      • 5.1.4.1.2. Vaccines
      • 5.1.4.1.3. Cell and Gene Therapy
      • 5.1.4.2. Academic Research Studies
      • 5.1.4.3. Biopharmaceutical Production
      • 5.1.4.4. Biotechnology Research
      • 5.1.4.5. Diagnostics
      • 5.1.4.6. Other Applications
    • 5.1.5. By End-user
      • 5.1.5.1. Pharmaceutical and Biotechnology Companies
      • 5.1.5.2. Academics and Research Institutions
      • 5.1.5.3. Clinical Research Organization
      • 5.1.5.4. Diagnostic Laboratories
      • 5.1.5.5. Others
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
      • 5.1.6.1.1. By Value
      • 5.1.6.1.2. By Volume
      • 5.1.6.2. By Product
      • 5.1.6.2.1. Cytokines and Growth Factors
      • 5.1.6.2.1.1. Interferons (IFNs)
      • 5.1.6.2.1.2. Interleukins (ILs)
      • 5.1.6.2.1.3. Others
      • 5.1.6.2.2. Antibodies
      • 5.1.6.2.3. Immune Checkpoint Proteins
      • 5.1.6.2.4. Virus Antigens
      • 5.1.6.2.5. Enzymes
      • 5.1.6.2.5.1. Kinases
      • 5.1.6.2.5.2. Metabolic enzymes
      • 5.1.6.2.5.3. Others
      • 5.1.6.2.6. Recombinant Regulatory Protein
      • 5.1.6.2.7. Hormones
      • 5.1.6.2.8. Others
      • 5.1.6.3. By Application
      • 5.1.6.3.1. Drug Discovery and Development
      • 5.1.6.3.1.1. Biologics
      • 5.1.6.3.1.2. Vaccines
      • 5.1.6.3.1.3. Cell and Gene Therapy
      • 5.1.6.3.2. Academic Research Studies
      • 5.1.6.3.3. Biopharmaceutical Production
      • 5.1.6.3.4. Biotechnology Research
      • 5.1.6.3.5. Diagnostics
      • 5.1.6.3.6. Other Applications
      • 5.1.6.4. By End-user
      • 5.1.6.4.1. Pharmaceutical and Biotechnology Companies
      • 5.1.6.4.2. Academics and Research Institutions
      • 5.1.6.4.3. Clinical Research Organization
      • 5.1.6.4.4. Diagnostic Laboratories
      • 5.1.6.4.5. Others
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered:

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia-Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Product
  • 6.2. By Host Cell
  • 6.3. By Application
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis - Volume and Value
  • 7.3. Supply/Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges, Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Abbvie Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Amgen Inc.
  • 13.3. Bio-Rad Laboratories Inc.
  • 13.4. Eli Lilly and Company
  • 13.5. Merck KGaA
  • 13.6. Novo Nordisk AS
  • 13.7. Sanofi SA
  • 13.8. Thermo Fisher Scientific Inc.
  • 13.9. Novartis AG
  • 13.10. GlaxoSmithKline PLC
  • 13.11. Novavax Inc.
  • 13.12. Pfizer Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 3. Global Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 4. Global Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 5. Global Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 6. Global Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Recombinant Proteins Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 10. North America Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 11. North America Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 12. North America Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 13. North America Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Recombinant Proteins Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 17. United States Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 18. United States Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 19. United States Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 20. United States Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 23. Canada Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 24. Canada Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 25. Canada Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 26. Canada Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 29. Mexico Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 30. Mexico Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 31. Mexico Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 32. Mexico Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 35. Europe Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 36. Europe Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 37. Europe Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 38. Europe Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Recombinant Proteins Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 42. Germany Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 43. Germany Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 44. Germany Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 45. Germany Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 48. France Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 49. France Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 50. France Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 51. France Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 54. Italy Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 55. Italy Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 56. Italy Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 57. Italy Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 60. United Kingdom Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 61. United Kingdom Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 62. United Kingdom Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 63. United Kingdom Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 66. Russia Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 67. Russia Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 68. Russia Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 69. Russia Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 72. Netherlands Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 73. Netherlands Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 74. Netherlands Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 75. Netherlands Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 78. Spain Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 79. Spain Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 80. Spain Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 81. Spain Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 84. Turkey Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 85. Turkey Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 86. Turkey Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 87. Turkey Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 90. Poland Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 91. Poland Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 92. Poland Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 93. Poland Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 96. South America Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 97. South America Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 98. South America Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 99. South America Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Recombinant Proteins Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 103. Brazil Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 104. Brazil Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 105. Brazil Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 106. Brazil Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 109. Argentina Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 110. Argentina Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 111. Argentina Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 112. Argentina Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 115. Asia-Pacific Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 116. Asia-Pacific Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 117. Asia-Pacific Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 118. Asia-Pacific Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Recombinant Proteins Market Share (%), By Country, 2017-2031F
  • Figure 120. India Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 122. India Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 123. India Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 124. India Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 125. India Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 128. China Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 129. China Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 130. China Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 131. China Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 134. Japan Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 135. Japan Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 136. Japan Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 137. Japan Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 140. Australia Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 141. Australia Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 142. Australia Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 143. Australia Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 146. Vietnam Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 147. Vietnam Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 148. Vietnam Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 149. Vietnam Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 152. South Korea Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 153. South Korea Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 154. South Korea Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 155. South Korea Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 158. Indonesia Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 159. Indonesia Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 160. Indonesia Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 161. Indonesia Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 164. Philippines Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 165. Philippines Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 166. Philippines Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 167. Philippines Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 170. Middle East & Africa Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 171. Middle East & Africa Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 172. Middle East & Africa Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 173. Middle East & Africa Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Recombinant Proteins Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 177. Saudi Arabia Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 178. Saudi Arabia Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 179. Saudi Arabia Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 180. Saudi Arabia Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 183. UAE Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 184. UAE Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 185. UAE Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 186. UAE Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Recombinant Proteins Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Recombinant Proteins Market, By Volume, In Millions, 2017-2031F
  • Figure 189. South Africa Recombinant Proteins Market Share (%), By Product, 2017-2031F
  • Figure 190. South Africa Recombinant Proteins Market Share (%), By Host Cell, 2017-2031F
  • Figure 191. South Africa Recombinant Proteins Market Share (%), By Application, 2017-2031F
  • Figure 192. South Africa Recombinant Proteins Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Host Cell Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023